Clinical Breast Exam Rarely Detects Second Breast Cancer After DCIS
FRIDAY, Jan. 12, 2024 -- For patients undergoing surveillance following diagnosis and treatment of ductal carcinoma in situ (DCIS), very few second breast cancers are detected by clinical breast examination by a physician, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 12, 2024 Category: Pharmaceuticals Source Type: news

Clinical Exams Fall Short in Second Breast Cancer Detection Clinical Exams Fall Short in Second Breast Cancer Detection
A decade-long surveillance study shows clinical breast examinations are largely ineffective in detecting second cancers in women treated for ductal carcinoma in situ.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Benign breast disease found on percutaneous biopsy ups cancer risk
Benign breast disease diagnosed through percutaneous biopsy increases the overall risk of developing breast cancer, according to research published December 13 in JAMA Surgery.  A team led by Dr. Mark Sherman from the Mayo Clinic in Jacksonville, FL, found that presence of the disease on percutaneous biopsy is tied to a similar degree of increased breast cancer risk compared with surgically diagnosed benign breast disease. It also reported that the risks of both invasive breast cancer and ductal carcinoma in situ (DCIS) remained elevated among patients with the disease compared with the general population. “The finding...
Source: AuntMinnie.com Headlines - December 13, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Source Type: news

Oncotype Score Helps Avoid Unnecessary Radiation in DCIS Oncotype Score Helps Avoid Unnecessary Radiation in DCIS
Using a gene test to guide radiation decisions may reduce overtreatment in ductal carcinoma in situ.Medscape Medical News (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - December 11, 2023 Category: OBGYN Tags: Hematology-Oncology Source Type: news

Women With Very Early Breast Cancer May Safely Skip Radiation Rx: Study
FRIDAY, Dec. 8, 2023 -- Some women with a very early form of breast cancer known as ductal carcinoma in situ (DCIS) can safely skip follow-up radiation therapy after surgery, new research suggests.Results from a sophisticated genetic test are key... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 8, 2023 Category: General Medicine Source Type: news

CEM shows value as surveillance imaging tool
Contrast-enhanced mammography (CEM) has utility as a surveillance tool for women with a personal history of breast cancer, according to research presented December 6 at the San Antonio Breast Cancer Symposium.  In her talk, Julia Matheson from the University of Melbourne in Australia shared research indicating that CEM surveillance leads to increased detection of clinically significant breast lesions, as well as lower interval cancer rates. “CEM increases the sensitivity of surveillance programs for women with a personal history of breast cancer,” Matheson said.  Annual mammography with or without supplemental ultra...
Source: AuntMinnie.com Headlines - December 6, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Breast Source Type: news

Biomarker model predicts breast cancer risk without racial bias
CHICAGO -- A new breast cancer risk assessment technique that uses mammography biomarkers shows no racial bias, according to research presented November 29 at the RSNA meeting.The findings offer another way to foster breast cancer early detection, improve patient survival rates across different populations, and reduce disparity in survival rates, said study lead author Leslie Lamb, MD, of Massachusetts General Hospital (MGH) in Boston in a statement. “In the domain of precision medicine, risk-based screening has been elusive because we have not been able to accurately evaluate a woman’s risk of developing breast cance...
Source: AuntMinnie.com Headlines - November 29, 2023 Category: Radiology Authors: Liz Carey Tags: Subspecialties Womens Imaging Breast Imaging RSNA 2023 Source Type: news

ASTRO proposes new guidelines for aggressive breast cancer and DCIS
The American Society for Radiation Oncology (ASTRO) has released a proposed update to clinical practice guidelines for partial breast radiation as an alternative to whole breast radiation for early-stage invasive breast cancer and ductal carcinoma in situ (DCIS). ASTRO’s recommendations are based on evidence from major clinical trials, said Janice Lyons, MD, chair of the guideline task force at the University Hospitals Seidman Cancer Center in Cleveland, OH, in a statement released by the society. The new guidance also addresses aspects related to the technical delivery of partial breast irradiation (PBI), including do...
Source: AuntMinnie.com Headlines - November 17, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Radiation Oncology Source Type: news

ASTRO Updates Guidelines on Partial Breast Irradiation for Early Invasive Cancer
(MedPage Today) -- The American Society for Radiation Oncology (ASTRO) updated their guidelines on partial breast irradiation (PBI) for patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). These new guidelines take... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news

Mammography-based nomogram predicts breast microcalcifications
A mammography-based radiomic nomogram could be useful in predicting risk of malignancy in suspicious breast microcalcifications, according to research published November 7 in Academic Radiology. A team led by Yusi Chen from the Second Affiliated Hospital of Harbin Medical University in China found that the nomogram, which combined radiomic scoring with clinical factors, achieved a high area under the curve (AUC) value in a validation set of patients with breast microcalcifications. “The combined model could be considered as a potential imaging marker to predict malignant risk,” Chen and colleagues wrote. Differentia...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Advanced Visualization Breast Imaging Source Type: news

Ductal Carcinoma in Situ (DCIS): What It Is, Causes, Symptoms & Treatment
A breast cancer diagnosis can be terrifying, but one type of early-stage disease is noninvasive and has high survival odds. There have been an estimated 297,790 new cases of breast cancer diagnosed in the United States so far this year, the U.S.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2023 Category: General Medicine Source Type: news

Scientists Say They ’ve Reached ‘Turning Point’ in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine. After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years. These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer. “We’re getting something to work. Now we need to get it to work better,” said Dr. James Gulley, who help...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news

Scientists Say They ’ve Reached Turning Point in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine. After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years. These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer. More from TIME [video id=W5jcvwLu autostart="viewable"] “We’re getting something to work. Now we need to get...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news

Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 -- (Healthcare Sales & Marketing Network) -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leadin... Biopharmaceuticals, Oncology Sirnaomics, RNAi therapeutics, squamous cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 19, 2023 Category: Pharmaceuticals Source Type: news

SBI: The presence of LCIS indicates increased breast cancer risk
Lobular carcinoma in situ (LCIS) is both a cancer precursor indicator and ...Read more on AuntMinnie.comRelated Reading: Is screening breast MRI needed for women with high-risk lesions? How should architectural distortions on DBT be managed? FES-PET/CT can help detect breast cancer Chest wall ultrasound good alternative after mastectomy AI, breast density assessment spot more interval cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 9, 2023 Category: Radiology Source Type: news